SOUTH SAN FRANCISCO, Calif., June
30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ:IDYA), an oncology-focused precision medicine company
committed to the discovery and development of targeted therapeutics
based on Synthetic Lethality, announced the appointment of
Garret Hampton, Ph.D., to its Board
of Directors.
Dr. Hampton brings over 25 years of industry experience and
currently serves as President, Clinical Sequencing and Oncology at
Thermo Fisher Scientific. He previously served as Senior Vice
President, Clinical Genomics at Illumina. Prior to Ilumina,
Dr. Hampton was the Global Head of Oncology Biomarker Development
and Companion Diagnostics at Genentech / Roche and chair of the Roche /
Foundation Medicine Joint R&D Committee. Through these roles,
Dr. Hampton has become a thought leader in the area of precision
medicine oncology, including next generation sequencing, cancer
genomics, and companion diagnostics.
"Garret brings deep industry experience from translational
research, biomarker discovery and validation to approved companion
diagnostics, and this wealth of knowledge will be invaluable to
IDEAYA as it advances its broad pipeline of Synthetic Lethality
programs into the clinic, each with a molecularly-defined biomarker
hypothesis," said Tim Shannon, M.D.,
Chairman of IDEAYA's Board of Directors.
IDEAYA believes global access to molecular diagnostics for
oncology patients, particularly in Asia, is key to the development of targeted
oncology medicines. The company continues to advance its
Genomics Profiling Initiative (GPI) – leveraging various molecular
platforms to identify patients that are most likely to benefit
from the company's Synthetic Lethality programs, including
MTAP-deletion which is present in approximately 15% of all solid
tumors.
"Garret's expertise in the area of biomarker discovery and
development will be instrumental as we advance our MAT2A Synthetic
Lethality program into the clinic targeting the MTAP-deletion
patient population, as well as pursue our broader global strategy
to identify novel Synthetic Lethal targets and patient biomarkers,"
said Yujiro S. Hata, President and
Chief Executive Officer, at IDEAYA.
"IDEAYA is a leader in Synthetic Lethality, an emerging field of
precision medicine oncology. Synthetic Lethality includes
exciting new opportunities in translational research and biomarker
discovery, all areas that are anticipated to flourish with the
enhanced global access to next generation sequencing. I'm
delighted to join IDEAYA's Board of Directors as the company
advances its broad pipeline of Synthetic Lethality based therapies,
and pursues its mission to deliver transformative precision
medicines to cancer patients," said Dr. Hampton.
About IDEAYA Biosciences
IDEAYA is an oncology-focused
precision medicine company committed to the discovery and
development of Synthetic Lethality-based therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with small molecule drug discovery to
select patient populations most likely to benefit from the targeted
therapies IDEAYA is developing. IDEAYA is applying these
capabilities across multiple classes of precision medicine,
including synthetic lethality – which represents an emerging class
of precision medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) the role of molecular diagnostics in the
development of targeted oncology medicines and (ii) the effect of
Dr. Hampton's expertise on IDEAYA's programs. Such forward-looking
statements involve substantial risks and uncertainties that could
cause IDEAYA's preclinical and clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the
uncertainties inherent in the drug development process, including
IDEAYA's programs' early stage of development, the process of
designing and conducting preclinical and clinical trials, the
regulatory approval processes, the timing of regulatory filings,
the challenges associated with manufacturing drug products,
IDEAYA's ability to successfully establish, protect and defend its
intellectual property and other matters that could affect the
sufficiency of existing cash to fund operations. IDEAYA undertakes
no obligation to update or revise any forward-looking statements.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's recent Quarterly Report
on Form 10-Q filed on May 12, 2020,
and any current and periodic reports filed with the U.S. Securities
and Exchange Commission.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-appoints-garret-hampton-phd-to-the-board-of-directors-an-industry-leader-in-precision-medicine-oncology-and-diagnostics-301085509.html
SOURCE IDEAYA Biosciences, Inc.